Integrative bioinformatics analysis and experimental validation of key biomarkers driving the progression of cirrhotic portal hypertension
Source check: Source checked. Not independent scientific confirmation.
Finding: The study reports OIT3 and LOXL1 as candidate cirrhotic portal-hypertension biomarkers and links them with disease-associated expression and pathways. The authors report an independent GEO cohort and clinical-tissue RT-qPCR/IHC. OIT3 replicated, while LOXL1 expression and diagnostic performance did not replicate adequately (validation AUC 0.6169); this limits the claim.
Technology: LASSO, random forest and SVM-RFE screened transcriptomic candidate genes; their intersection selected OIT3 and LOXL1 for subsequent testing.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- LASSO, random forest and SVM-RFE screened transcriptomic candidate genes; their intersection selected OIT3 and LOXL1 for subsequent testing.
- Test and result
- The study reports OIT3 and LOXL1 as candidate cirrhotic portal-hypertension biomarkers and links them with disease-associated expression and pathways.
- Limitation / still unknown
- The authors report an independent GEO cohort and clinical-tissue RT-qPCR/IHC. OIT3 replicated, while LOXL1 expression and diagnostic performance did not replicate adequately (validation AUC 0.6169); this limits the claim.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://peerj.com/articles/19360
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary source full text Methods and Results; version/date checked against bibliographic record..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.